678 Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial

西妥昔单抗 医学 内科学 耐火材料(行星科学) 头颈部鳞状细胞癌 肿瘤科 临床终点 队列 无进展生存期 临床研究阶段 临床试验 头颈部癌 胃肠病学 放射治疗 化疗 癌症 物理 结直肠癌 天体生物学
作者
Ye Guo,Qiang Li,Desheng Hu,Song Qu,Youhua Zhu,Meiyu Fang,Wantao Chen,Chuan-Zheng Sun,Hao Jiang,Jingfeng Zong,Jinguan Lin,Siyang Wang,Wei Wang,Chuan Jin,Guochun Cao,Minghua Ge,Xiaoming Huang,Xudong Wang,Zhiming Li,Mo Wang,Xianming Luo,Shuang-Hui Wei,Yuteng Shen
标识
DOI:10.1136/jitc-2023-sitc2023.0678
摘要

Background

PD-1 inhibitors and EGFR inhibitors are effective and may provide potential synergy in R/M HNSCC. An open-label, multicenter phase Ib/II study of toripalimab (a humanized IgG4K monoclonal antibody specific for PD-1) with cetuximab was conducted in platinum-refractory or PD-L1 positive previously untreated R/M-HNSCC (NCT04856631). Here we report the results of Cohort A (platinum-refractory).

Methods

Eligible patients with R/M HNSCC progressed upon 1st-line platinum-containing treatment or developed R/M disease within 6 months of platinum-containing neo-adjuvant/adjuvant or chemo-radiation therapy who had no prior immunotherapy or EGFR inhibitors therapy were enrolled. Toripalimab was administered at 240mg intravenously (IV) Q3W and cetuximab was given as a loading dose of 400mg/m2 IV followed by 250mg/m2 QW. The primary endpoint was objective response rate (ORR) by an independent review committee (IRC) per RECIST v1.1. Secondary endpoints included ORR, disease control rates (DCR), duration of response (DOR), progression-free survival (PFS) by the investigators and IRC, overall survival (OS), and safety.

Results

By the data cutoff date of Apr. 14, 2023, a total of 45 patients including 35 (77.8%) males were enrolled in Cohort A, with the median follow-up duration of 10.0 months. The median age of the patients was 59 (range 32–74) years. Eighteen (40.0%) patients had distant metastases and 31 (68.9%) were PD-L1 CPS ≥1. As assessed by the IRC, the confirmed ORR was 60% (95% CI 44.3%, 74.3%) with 1 CR and 26 PR, and the median DOR was 17.9 (95% CI 7.8, NA) months, the median PFS was 9.9 (95% CI 4.2, NA) months, 12 months PFS rate was 40.7%. Similar results were seen per investigators' assessment. The median OS was 15.4 (95% CI 8.5, 17.7) months, 12 months OS rate was 54.4%. Patients with positive PD-L1 expression (CPS≥1) may benefit more than negative patients (ORR: 64.5% vs 40%, median PFS: 10.4 m vs 4.0 m, median OS: 15.4 m vs 11.7 m). Forty-two (93.3%) patients experienced treatment-related adverse events (TRAEs). Eleven (24.4%) patients experienced immune-related adverse events (irAEs). Ten (22.2%) patients occurred Grade≥3 TRAEs and no Grade≥3 irAEs occurred. No fatal AEs related to the study treatment was reported.

Conclusions

Toripalimab combined with cetuximab were well tolerated and showed promising clinical efficacy in patients with R/M HNSCC.

Trial Registration

NCT04856631

Ethics Approval

The study obtained ethics approval from Shanghai East Hospital Drug clinical Trial Ethics Committee [[2020]&x4E34;&x5BA1;&x7B2C; (072) &x53F7;], and participants gave informed consent before taking part.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bang发布了新的文献求助10
1秒前
刘佳敏发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
伊斯坦布尔的鱼应助安宇采纳,获得10
2秒前
嗯嗯完成签到,获得积分10
3秒前
情怀应助瑶瑶采纳,获得10
4秒前
rundstedt完成签到 ,获得积分10
4秒前
还不错发布了新的文献求助10
4秒前
4秒前
思源应助niu采纳,获得10
4秒前
niuwenyu发布了新的文献求助10
4秒前
田様应助Deadman采纳,获得10
5秒前
6秒前
6秒前
elysia发布了新的文献求助10
7秒前
幽默胜完成签到,获得积分10
7秒前
跳跃完成签到 ,获得积分10
7秒前
7秒前
我是老大应助王先森采纳,获得10
8秒前
tjzbw完成签到,获得积分10
8秒前
甜美孤丹发布了新的文献求助10
8秒前
8秒前
所所应助Gengar采纳,获得10
8秒前
超级馒头应助Gengar采纳,获得10
8秒前
缓慢如南应助Gengar采纳,获得10
8秒前
8秒前
8秒前
zhang08完成签到,获得积分10
8秒前
狐狐完成签到,获得积分10
9秒前
9秒前
9秒前
DD应助123456采纳,获得10
10秒前
10秒前
10秒前
Triste完成签到,获得积分20
10秒前
Jasper应助还不错采纳,获得10
10秒前
10秒前
小龙人发布了新的文献求助10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3971091
求助须知:如何正确求助?哪些是违规求助? 3515797
关于积分的说明 11179488
捐赠科研通 3250872
什么是DOI,文献DOI怎么找? 1795536
邀请新用户注册赠送积分活动 875891
科研通“疑难数据库(出版商)”最低求助积分说明 805207